Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

TRAP1 chaperone protein mutations and autoinflammation.

Standing AS, Hong Y, Paisan-Ruiz C, Omoyinmi E, Medlar A, Stanescu H, Kleta R, Rowcenzio D, Hawkins P, Lachmann H, McDermott MF, Eleftheriou D, Klein N, Brogan PA.

Life Sci Alliance. 2019 Dec 27;3(2). pii: e201900376. doi: 10.26508/lsa.201900376. Print 2020 Feb.

2.

ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis.

Scambler T, Jarosz-Griffiths HH, Lara-Reyna S, Pathak S, Wong C, Holbrook J, Martinon F, Savic S, Peckham D, McDermott MF.

Elife. 2019 Sep 18;8. pii: e49248. doi: 10.7554/eLife.49248.

3.

Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation.

Lara-Reyna S, Scambler T, Holbrook J, Wong C, Jarosz-Griffiths HH, Martinon F, Savic S, Peckham D, McDermott MF.

Front Immunol. 2019 Aug 2;10:1789. doi: 10.3389/fimmu.2019.01789. eCollection 2019.

4.

TNF receptor signalling in autoinflammatory diseases.

Jarosz-Griffiths HH, Holbrook J, Lara-Reyna S, McDermott MF.

Int Immunol. 2019 Sep 18;31(10):639-648. doi: 10.1093/intimm/dxz024.

PMID:
30838383
5.

ER Stress: A Therapeutic Target in Rheumatoid Arthritis?

Rahmati M, Moosavi MA, McDermott MF.

Trends Pharmacol Sci. 2018 Jul;39(7):610-623. doi: 10.1016/j.tips.2018.03.010. Epub 2018 Apr 23. Review.

PMID:
29691058
6.

Autoinflammatory disease in the lung.

Scambler T, Holbrook J, Savic S, McDermott MF, Peckham D.

Immunology. 2018 Apr 19. doi: 10.1111/imm.12937. [Epub ahead of print] Review.

7.

Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.

Harrison SR, Scambler T, Oubussad L, Wong C, Wittmann M, McDermott MF, Savic S.

Front Immunol. 2018 Feb 6;9:173. doi: 10.3389/fimmu.2018.00173. eCollection 2018.

8.

Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2.

Gillespie J, Ross RL, Corinaldesi C, Esteves F, Derrett-Smith E, McDermott MF, Doody GM, Denton CP, Emery P, Del Galdo F.

Arthritis Rheumatol. 2018 Jun;70(6):932-942. doi: 10.1002/art.40437. Epub 2018 Apr 23.

9.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
10.

Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis.

Ouboussad L, Hunt L, Hensor EMA, Nam JL, Barnes NA, Emery P, McDermott MF, Buch MH.

Arthritis Res Ther. 2017 Dec 22;19(1):288. doi: 10.1186/s13075-017-1492-9.

11.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

12.

Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathway.

West C, McDermott MF.

Biosci Rep. 2017 Jul 12;37(4). pii: BSR20170180. doi: 10.1042/BSR20170180. Print 2017 Aug 31.

13.

Protection against lupus-like inflammatory disease is in the LAP of non-canonical autophagy.

Scambler T, Feeley C, McDermott MF.

Ann Transl Med. 2016 Dec;4(24):513. doi: 10.21037/atm.2016.12.30. No abstract available.

14.

Corticosteroid transdermal delivery significantly improves arthritis pain and functional disability.

Iannitti T, McDermott MF, Laurino C, Malagoli A, Palmieri B.

Drug Deliv Transl Res. 2017 Feb;7(1):156-161. doi: 10.1007/s13346-016-0340-9.

15.

Lessons from characterization and treatment of the autoinflammatory syndromes.

Aksentijevich I, McDermott MF.

Curr Opin Rheumatol. 2017 Mar;29(2):187-194. doi: 10.1097/BOR.0000000000000362. Review.

16.

Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.

Harrison SR, McGonagle D, Nizam S, Jarrett S, van der Hilst J, McDermott MF, Savic S.

JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.

17.

The burgeoning field of innate immune-mediated disease and autoinflammation.

Peckham D, Scambler T, Savic S, McDermott MF.

J Pathol. 2017 Jan;241(2):123-139. doi: 10.1002/path.4812. Epub 2016 Nov 11. Review.

18.

Autoinflammatory diseases: update on classification diagnosis and management.

Pathak S, McDermott MF, Savic S.

J Clin Pathol. 2017 Jan;70(1):1-8. doi: 10.1136/jclinpath-2016-203810. Epub 2016 Sep 19. Review.

19.

Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond.

Agyemang AF, Harrison SR, Siegel RM, McDermott MF.

Semin Immunopathol. 2015 Jul;37(4):335-47. doi: 10.1007/s00281-015-0496-2. Epub 2015 May 21. Review.

20.

Clinical genetics in 2014: New monogenic diseases span the immunological disease continuum.

Savic S, McDermott MF.

Nat Rev Rheumatol. 2015 Feb;11(2):67-8. doi: 10.1038/nrrheum.2014.215. Epub 2014 Dec 23.

PMID:
25536483
21.

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.

Sedger LM, McDermott MF.

Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72. doi: 10.1016/j.cytogfr.2014.07.016. Epub 2014 Aug 1. Review.

22.

TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes.

Savic S, Ouboussad L, Dickie LJ, Geiler J, Wong C, Doody GM, Churchman SM, Ponchel F, Emery P, Cook GP, Buch MH, Tooze RM, McDermott MF.

J Autoimmun. 2014 May;50:59-66. doi: 10.1016/j.jaut.2013.11.002. Epub 2013 Dec 31.

23.

First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G, Muscari I, Magnotti F, Dickie LJ, Galeazzi M, Negrini M, Baldari CT, Cimaz R, Cantarini L.

PLoS One. 2013 Sep 16;8(9):e73443. doi: 10.1371/journal.pone.0073443. eCollection 2013.

24.

IL-17A RNA aptamer: possible therapeutic potential in some cells, more than we bargained for in others?

Doble R, McDermott MF, Cesur Ö, Stonehouse NJ, Wittmann M.

J Invest Dermatol. 2014 Mar;134(3):852-855. doi: 10.1038/jid.2013.399. Epub 2013 Sep 20. No abstract available.

25.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
26.

Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene.

Rittore C, Sanchez E, Soler S, Barat-Houari M, Albers M, Obici L, McDermott MF, Touitou I, Grandemange S.

Ann Rheum Dis. 2014 Jan;73(1):290-7. doi: 10.1136/annrheumdis-2012-203023. Epub 2013 Mar 16.

27.

Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives.

Savic S, Dickie LJ, Wittmann M, McDermott MF.

Best Pract Res Clin Rheumatol. 2012 Aug;26(4):505-33. doi: 10.1016/j.berh.2012.07.009.

PMID:
23040364
28.

Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.

Coulthard LR, Geiler J, Mathews RJ, Church LD, Dickie LJ, Cooper DL, Wong C, Savic S, Bryer D, Buch MH, Emery P, Morgan AW, McDermott MF.

Clin Exp Immunol. 2012 Oct;170(1):36-46. doi: 10.1111/j.1365-2249.2012.04626.x.

29.

Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor.

Churchman SM, Geiler J, Parmar R, Horner EA, Church LD, Emery P, Buch MH, McDermott MF, Ponchel F.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4):534-42. Epub 2012 Aug 29.

PMID:
22704737
30.

Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome.

Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J, Wong CH, Coughlan R, Lane T, Lachmann HJ, Hawkins PN, Robinson PA, Emery P, McGonagle D, McDermott MF.

Ann Rheum Dis. 2012 Dec;71(12):2035-43. doi: 10.1136/annrheumdis-2011-201197. Epub 2012 Jun 7.

PMID:
22679299
31.

The role of the NLRP3 inflammasome in gout.

Kingsbury SR, Conaghan PG, McDermott MF.

J Inflamm Res. 2011;4:39-49. doi: 10.2147/JIR.S11330. Epub 2011 Mar 13.

32.

Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases.

Savic S, Dickie LJ, Battellino M, McDermott MF.

Curr Opin Rheumatol. 2012 Jan;24(1):103-12. doi: 10.1097/BOR.0b013e32834dd2d5. Review.

PMID:
22089100
33.
34.

Anti-TNF treatment in rheumatoid arthritis.

Geiler J, Buch M, McDermott MF.

Curr Pharm Des. 2011;17(29):3141-54. Review.

PMID:
21864263
35.

Is caspase 1 central to activation of interleukin-1?

Wittmann M, Kingsbury SR, McDermott MF.

Joint Bone Spine. 2011 Jul;78(4):327-30. doi: 10.1016/j.jbspin.2011.02.004. Epub 2011 Apr 3. No abstract available.

PMID:
21459652
36.

Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients.

Nedjai B, Hitman GA, Church LD, Minden K, Whiteford ML, McKee S, Stjernberg S, Pettersson T, Ranki A, Hawkins PN, Arkwright PD, McDermott MF, Turner MD.

Cell Immunol. 2011;268(2):55-9. doi: 10.1016/j.cellimm.2011.02.007. Epub 2011 Mar 1.

PMID:
21420073
37.

Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome.

Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF, McGonagle D.

Ann Rheum Dis. 2011 Sep;70(9):1692-3. doi: 10.1136/ard.2010.144279. Epub 2011 Mar 6. No abstract available.

PMID:
21378401
38.

Inflammasomes and autoimmunity.

Shaw PJ, McDermott MF, Kanneganti TD.

Trends Mol Med. 2011 Feb;17(2):57-64. doi: 10.1016/j.molmed.2010.11.001. Epub 2010 Dec 14. Review.

39.
40.

Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A.

Nedjai B, Quillinan N, Coughlan RJ, Church L, McDermott MF, Hitman GA, Turner MD.

Adv Exp Med Biol. 2011;691:409-19. doi: 10.1007/978-1-4419-6612-4_43. No abstract available.

PMID:
21153346
41.

Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.

Church LD, McDermott MF.

Expert Rev Clin Immunol. 2010 Nov;6(6):831-41. doi: 10.1586/eci.10.66.

PMID:
20979548
42.

Periodic fever syndrome and autoinflammatory diseases.

Dickie LJ, Savic S, Aziz A, Sprakes M, McDermott MF.

F1000 Med Rep. 2010 Jan 18;2. pii: 3. doi: 10.3410/M2-3.

43.

Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients.

Coulthard LR, Taylor JC, Eyre S; Biologics in Rheumatoid Arthritis Genetics and Genomics, Robinson JI, Wilson AG, Isaacs JD, Hyrich K, Emery P, Barton A, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2011 Jan;70(1):98-103. doi: 10.1136/ard.2010.133249. Epub 2010 Aug 30.

PMID:
20805296
44.

Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes.

Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF.

Rheumatology (Oxford). 2010 Aug;49(8):1466-71. doi: 10.1093/rheumatology/keq124. Epub 2010 Apr 30.

PMID:
20435648
45.

The NLRP3 inflammasome, a target for therapy in diverse disease states.

Cook GP, Savic S, Wittmann M, McDermott MF.

Eur J Immunol. 2010 Mar;40(3):631-4. doi: 10.1002/eji.200940162. Review.

46.

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).

Gillespie J, Mathews R, McDermott MF.

J Inflamm Res. 2010;3:1-8. Epub 2010 Jan 19.

47.

Imaging evidence for persistent subclinical fasciitis and arthritis in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) between febrile attacks.

Quillinan N, Mohammad A, Mannion G, O'Keeffe D, Bergin D, Coughlan R, McDermott MF, McGonagle D.

Ann Rheum Dis. 2010 Jul;69(7):1408-9. doi: 10.1136/ard.2009.118661. Epub 2009 Nov 12. No abstract available.

PMID:
19914902
48.

Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.

Savic S, McDermott MF.

Nat Rev Rheumatol. 2009 Oct;5(10):529-30. doi: 10.1038/nrrheum.2009.195. No abstract available.

PMID:
19798026
49.
50.

p38(MAPK): stress responses from molecular mechanisms to therapeutics.

Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA.

Trends Mol Med. 2009 Aug;15(8):369-79. doi: 10.1016/j.molmed.2009.06.005. Epub 2009 Aug 6. Review.

Supplemental Content

Loading ...
Support Center